Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
Erik J.M. van Bommel, Marcel H.A. Muskiet, Lennart Tonneijck, et al.
Clinical Journal of the American Society of Nephrology (2017) Vol. 12, Iss. 4, pp. 700-710
Open Access | Times Cited: 204

Showing 1-25 of 204 citing articles:

Chronic kidney disease
Paola Romagnani, Giuseppe Remuzzi, Richard J. Glassock, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Open Access | Times Cited: 770
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, et al.
Nature Reviews Nephrology (2017) Vol. 13, Iss. 10, pp. 605-628
Closed Access | Times Cited: 314
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar, et al.
Kidney International (2019) Vol. 97, Iss. 1, pp. 202-212
Open Access | Times Cited: 292
Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment
Mihai-Emil Gherghina, Ileana Peride, Mirela Ţigliş, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3188-3188
Open Access | Times Cited: 237
A more tubulocentric view of diabetic kidney disease
Letizia Zeni, Anthony G.W. Norden, Giovanni Cancarini, et al.
Journal of Nephrology (2017) Vol. 30, Iss. 6, pp. 701-717
Open Access | Times Cited: 224
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Michaël J.B. van Baar, Charlotte C. van Ruiten, Marcel H.A. Muskiet, et al.
Diabetes Care (2018) Vol. 41, Iss. 8, pp. 1543-1556
Open Access | Times Cited: 171
Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus
Thea Anine Strøm Halden, Kine Eide Kvitne, Karsten Midtvedt, et al.
Diabetes Care (2019) Vol. 42, Iss. 6, pp. 1067-1074
Open Access | Times Cited: 170
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
Anne C. Hesp, Jennifer A. Schaub, Pottumarthi V. Prasad, et al.
Kidney International (2020) Vol. 98, Iss. 3, pp. 579-589
Open Access | Times Cited: 146
Diabetic Kidney Disease: Challenges, Advances, and Opportunities
Ya Chen, Kyung Lee, Zhaohui Ni, et al.
Kidney Diseases (2020) Vol. 6, Iss. 4, pp. 215-225
Open Access | Times Cited: 141
Diabetic Kidney Disease
Sonali Gupta, Mary Dominguez, Ladan Golestaneh
Medical Clinics of North America (2023) Vol. 107, Iss. 4, pp. 689-705
Closed Access | Times Cited: 116
Hypoxia and chronic kidney disease
Bin Wang, Zuo‐Lin Li, Yilin Zhang, et al.
EBioMedicine (2022) Vol. 77, pp. 103942-103942
Open Access | Times Cited: 84
SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function
Danii L. S. Suijk, Michaël J.B. van Baar, Erik J.M. van Bommel, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 5, pp. 663-671
Open Access | Times Cited: 70
Combination therapy for kidney disease in people with diabetes mellitus
Daniël H. van Raalte, Petter Bjornstad, David Z.I. Cherney, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 37
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Paola Cassis, Monica Locatelli, Domenico Cerullo, et al.
JCI Insight (2018) Vol. 3, Iss. 15
Open Access | Times Cited: 147
Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Habib Yaribeygi, Alexandra E. Butler, Stephen L. Atkin, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 1, pp. 223-230
Open Access | Times Cited: 130
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Jingwei Li, Mark Woodward, Vlado Perkovic, et al.
JACC Heart Failure (2019) Vol. 8, Iss. 1, pp. 57-66
Open Access | Times Cited: 123
Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus
T. Cooper Woods, Ryousuke Satou, Kayoko Miyata, et al.
American Journal of Nephrology (2019) Vol. 49, Iss. 4, pp. 331-342
Open Access | Times Cited: 109
New pharmacological strategies for protecting kidney function in type 2 diabetes
Marcel H.A. Muskiet, David C. Wheeler, Hiddo J.L. Heerspink
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 5, pp. 397-412
Open Access | Times Cited: 97
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
Rosalie A. Scholtes, Marcel H.A. Muskiet, Michiel J.B. van Baar, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 440-447
Open Access | Times Cited: 95
Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial
Anne Zanchi, Michel Burnier, Müller Me, et al.
Journal of the American Heart Association (2020) Vol. 9, Iss. 13
Open Access | Times Cited: 83
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Erind Gjermeni, Anna Kirstein, Florentien Kolbig, et al.
Biomolecules (2021) Vol. 11, Iss. 10, pp. 1426-1426
Open Access | Times Cited: 66
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 53
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience
Ana Palanca, Falco van Nes, Felipe Pardo, et al.
Diabetes Care (2022) Vol. 45, Iss. 3, pp. 650-658
Open Access | Times Cited: 41
Cardiorenal benefits of finerenone: protecting kidney and heart
José Ramón González‐Juanatey, José Luis Górriz, Alberto Ortíz, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 502-513
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top